BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9412619)

  • 41. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants.
    Turagam MK; Velagapudi P; Flaker GC
    Clin Interv Aging; 2015; 10():1431-44. PubMed ID: 26366064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation.
    Yamagishi SI
    Cardiovasc Diabetol; 2019 Jan; 18(1):12. PubMed ID: 30691466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials.
    Ntaios G; Papavasileiou V; Diener HC; Makaritsis K; Michel P
    Stroke; 2012 Dec; 43(12):3298-304. PubMed ID: 23150654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.
    Ezekowitz MD; James KE; Nazarian SM; Davenport J; Broderick JP; Gupta SR; Thadani V; Meyer ML; Bridgers SL
    Circulation; 1995 Oct; 92(8):2178-82. PubMed ID: 7554199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
    Escobar C; Martí-Almor J; Pérez Cabeza A; Martínez-Zapata MJ
    Rev Esp Cardiol (Engl Ed); 2019 Apr; 72(4):305-316. PubMed ID: 29606361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cochrane corner: vitamin K for improved anticoagulation control in patients receiving warfarin.
    Mahtani KR; Nunan D; Heneghan C
    Heart; 2015 Nov; 101(21):1689-90. PubMed ID: 26135804
    [No Abstract]   [Full Text] [Related]  

  • 51. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
    Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
    Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New oral anticoagulants in elderly patients with atrial fibrillation.
    Deedwania PC
    Am J Med; 2013 Apr; 126(4):289-96. PubMed ID: 23369212
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 55. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis.
    Telles-Garcia N; Dahal K; Kocherla C; Lip GYH; Reddy P; Dominic P
    Int J Cardiol; 2018 Oct; 268():143-148. PubMed ID: 30041779
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.
    Hylek EM; Skates SJ; Sheehan MA; Singer DE
    N Engl J Med; 1996 Aug; 335(8):540-6. PubMed ID: 8678931
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Underutilization of anticoagulation therapy in chronic atrial fibrillation.
    Guo GB; Chang HW; Chen MC; Yang CH
    Jpn Heart J; 2001 Jan; 42(1):55-65. PubMed ID: 11324807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants.
    Forslund T; Komen JJ; Andersen M; Wettermark B; von Euler M; Mantel-Teeuwisse AK; Braunschweig F; Hjemdahl P
    Stroke; 2018 Sep; 49(9):2122-2128. PubMed ID: 30354995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.